Most of lymphoma patients including Non-Hodgkin's lymphoma show dysfunction in immunity especially after chemotherapy resulting in lack of responses to treatment and tumor relapse. This pilot study was aimed to measure gene array profiling of IL-1 and PG pathways in PBMCS of NHL patients and correlate the changes between them and clinical responses. This pilot study was conducted on 9 patients with Non-Hodgkin's lymphoma; using chemotherapy (CHOP). And using Affymetrix microarray for global total RNA profiling in lymphoma patients and for confirmed the Real-time PCR (RT-PCR). Microarray analysis showed that gene expression of IL-1 pathways such as NFKB-1and PELI-1 at early diagnosed group were downregulated compared to healthy control, then they upregulated during chemotherapy compared to early diagnosed however, they downregulated after chemotherapy compared to healthy control. On the other hand, CASP-1, IL-1A and CCL2 gene expression was downregulated in early diagnosed group compared to healthy control but they upregulated after chemotherapy.
Gene expression of Prostaglandin pathway such as EDN1 and PTGER2 were downregulated in early diagnosed group compared to healthy control, then it upregulated during chemotherapy compared to early diagnosed. However, PTGES-2 gene expression were downregulated compared to healthy control, then it upregulated during chemotherapy compared to early diagnosed and still upregulated after chemotherapy. That means chemotherapy has an impact on IL-1 and prostaglandin pathways which altered the gene expression.
Conclusion: Dysregulation of expression profile of both IL-1 and Prostaglandin pathways correlating them together with clinical responses is of paramount significance as biomarkers for prognosis of the disease.